There are currently 63 clinical trials in Doral, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Universal Axon Clinical Research, Integrity Clinical Research, LLC, Prohealth Research Center and Moonshine Research Center, Inc.. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/28/2024
Locations: D&H Doral Research Center LLC, Doral, Florida
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Register for Updates
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
NCT05848258
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: Integrity Clinical Research, Doral, Florida
Conditions: Rheumatoid Arthritis
Register for Updates
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
NCT05415137
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: aTyr Investigative Site, Doral, Florida
Conditions: Pulmonary Sarcoidosis
Register for Updates
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
NCT05587309
Recruiting
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
01/30/2024
Locations: Research Site 91, Doral, Florida
Conditions: Erosive Esophagitis
Register for Updates
R-2487 in Patients With Rheumatoid Arthritis
NCT05961592
Recruiting
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/18/2024
Locations: St.Jude Clinical Research, Doral, Florida
Conditions: Arthritis, Rheumatoid
Register for Updates
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
NCT06223880
Recruiting
This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/16/2024
Locations: Clinical Research Site, Doral, Florida
Conditions: Major Depressive Disorder
Register for Updates
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
NCT05772520
Recruiting
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of TLL018 as therapy in 120 participants with moderate-to-severe PP.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/20/2023
Locations: D&H Doral Research Center LLC, Doral, Florida
Conditions: Plaque Psoriasis
Register for Updates
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03987763
Recruiting
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
07/25/2023
Locations: Bausch Site 07, Doral, Florida
Conditions: Psoriasis
Register for Updates
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03988439
Recruiting
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
07/25/2023
Locations: Bausch Site 7, Doral, Florida
Conditions: Psoriasis
Register for Updates
PyloPlus Urea Breath Test System Post Therapy Efficacy Confirmation Study
NCT05681689
Recruiting
This is a multi-center, non-randomized, open label study. Subjects will be enrolled if they are deemed eligible given the inclusion criteria. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. Subjects will be exposed to non-radioactive 13C-Urea with citric acid, and may submit a stool sample or undergo endoscopy for Rapid Urease Test and Histology samples. Center(s) will house a PyloPlus UBT Analyzer to document results. PyloPlus Analyze... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/03/2023
Locations: Dolphin Medical Research, Doral, Florida
Conditions: Helicobacter Pylori Infection, Post-Treatment, Efficacy
Register for Updates
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
NCT05276557
Recruiting
This is a multi-center, non-randomized, open label study. Subjects will be enrolled on a walk-in basis. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All children will be exposed to non-radioactive 13C-Urea with citric acid, and shall submit a stool sample. Centers will house a PyloPlus UBT Analyzer to document results. PyloPlus Analyzer results shall remain blinded to... Read More
Gender:
All
Ages:
Between 3 years and 17 years
Trial Updated:
05/03/2023
Locations: Dolphin Medical Research, Doral, Florida
Conditions: Helicobacter Pylori, Safety, Efficacy
Register for Updates
Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03596905
Recruiting
This study of the efficacy and safety of Plecanatide in children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C)
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/06/2023
Locations: Synergy Research Site, Doral, Florida
Conditions: Irritable Bowel Syndrome With Constipation
Register for Updates